SGMT
USDSagimet Biosciences Inc. Series A Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$7.530
Máximo
$7.670
Mínimo
$7.020
Volume
0.13M
Fundamentos da empresa
Capitalização de mercado
244.6M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
0.57M
Bolsa de valores
NGM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of
Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29
Clear Street analyst Kaveri Pohlman initiates coverage on Sagimet Biosciences with a Buy rating and announces Price Target of $29.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.